Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
November 25, 2020 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing...
Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan
November 06, 2020 08:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing...
Atea Pharmaceuticals Announces Closing of Initial Public Offering
November 03, 2020 16:01 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing...
Atea Pharmaceuticals Announces Pricing of Initial Public Offering
October 29, 2020 20:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing...
Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19
October 22, 2020 01:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to...
Atea Pharmaceuticals Appoints Polly Murphy, D.V.M, Ph.D., to the Board of Directors
September 14, 2020 06:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral...
Atea Pharmaceuticals Strengthens Management Team with Appointment of Clinical and Regulatory Leadership
August 24, 2020 06:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral...
Atea Pharmaceuticals Appoints Janet Hammond, M.D., Ph.D., as Chief Development Officer
August 10, 2020 06:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral...
Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing
May 20, 2020 06:00 ET
|
Atea Pharmaceuticals, Inc.
Proceeds to support the clinical development of Atea’s oral, direct acting antiviral medicine for COVID-19, in addition to advancing its diverse pipeline of treatments for viral...
Atea Pharmaceuticals to Present Positive Clinical Data with At-527 for the Treatment of Chronic Hepatitis C in Patients with Cirrhosis at The Liver Meeting ® 2018
November 09, 2018 08:01 ET
|
Atea Pharmaceuticals, Inc.
AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor AT-527 shows profound and equivalent pan-genotypic antiviral activity in cirrhotic and non-cirrhotic (NC) hepatitis...